Invertebral Disc Disease Clinical Trials

Find Invertebral Disc Disease Clinical Trials Near You

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease : A Pivotal, Randomized, Prospective, Multi-Center Study

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Device, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients with Lumbar Degenerative Disc Disease : A Pivotal, Randomized, Prospective, Multi-Center Study

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 80
Healthy Volunteers: f
View:

• Has a primary diagnosis of symptomatic lumbar degeneration with or without foraminal or recess stenosis of the lumbar confirmed by subject history and radiographic imaging (CT, MRI, X-rays) with no more than a Grade 2 (≤50% translation) spondylolisthesis. Symptomatic lumbar degeneration (L1 to S1) that may be associated with a co-morbid condition.

• Has a history of failure conservative treatment (e.g. bed rest, physical therapy, medications, transcutaneous electrical nerve stimulation (TENS), manipulation, and/or spinal injections) for at least 6 months

• Has preoperative Oswestry Disability Index score ≥ 40/100 at baseline

• Male or Female, 21-80 years of age and skeletally mature at the time of surgery

• Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms

• Signed informed consent

Locations
United States
Louisiana
The Spine Center of Louisiana
RECRUITING
Baton Rouge
LSU Health
RECRUITING
Shreveport
Pennsylvania
Thomas Jefferson University - Department of Neurological Surgery
RECRUITING
Philadelphia
Texas
American Neurospine Institute, PLLC
RECRUITING
Frisco
West Virginia
West Virginia University - Department of Orthopaedics
RECRUITING
Morgantown
Contact Information
Primary
Jumi Han
Jumi.Han@CGBioUSA.com
1.949.445.5965
Time Frame
Start Date: 2026-05
Estimated Completion Date: 2031-11
Participants
Target number of participants: 316
Treatments
Experimental: Novosis Putty
Active_comparator: Standard of Care
Related Therapeutic Areas
Sponsors
Leads: CGBio Inc.
Collaborators: CGBio USA

This content was sourced from clinicaltrials.gov